AAV vectors hold unparalleled potential to address a myriad of genetic disorders, neurodegenerative diseases, and cancers by delivering therapeutic genes with precision and efficacy. Improving AAV vectors is vital to producing targeted treatments with minimal side effects and the potential to cure previously untreatable or difficult-to-treat conditions. Enhanced AAV vectors could be the key to feasible personalized medicine and maximizing treatment outcomes.
In tandem with the refinement of AAV vectors themselves, strides are being made in enhancing the polishing and processing techniques vital for their recovery and growth. Innovations in downstream processing are streamlining production workflows, enabling scalability and cost-effectiveness crucial for clinical translation. Beyond enhancing the efficiency and scalability of AAV vector production, these efforts also help ensure the safety and efficacy of gene therapy products, accelerating their journey from bench to bedside. By continually refining the polishing and processing of AAV vectors, scientists and manufacturers are catalyzing the transformation of gene therapy from a promising concept to a tangible reality.
Download this resource guide to learn:
- A scalable process for AAV processing
- The many challenges of AAV processing and purification
- Lessons on optimizing AAV processing and purification
- How different AAV serotypes, cell types, and material choices affect AAV processing
- The current gene therapy applications of AAV vectors
- What the future holds for AAV gene therapy
